Genetically defined mouse models that mimic natural aspects of human prostate cancer development

被引:106
作者
Roy-Burman, P [1 ]
Wu, H
Powell, WC
Hagenkord, J
Cohen, MB
机构
[1] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA
[2] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA
[4] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA
关键词
D O I
10.1677/erc.0.0110225
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This review is focused on mouse models for prostate cancer that have been designed on the basis of genetic alterations that are frequently found in human prostate cancer. It begins with an analysis of the similarities and differences in the gross and microscopic anatomy of the mouse and human prostate glands, and extends to the pathologies induced in the genetically manipulated mouse prostate in comparison with the sporadic development of the disease in humans. Major achievements have been made in modeling human prostate cancer in mice in recent years. There are models which display slow, temporal development of increasingly severe preneoplastic lesions, which are remarkably restricted to the prostate gland, a property similar to the aging-related progression of these lesions in humans. Other models rapidly progress to local invasive adenocarcinoma, and, in some of them metastasis is manilested subsequently with defined kinetics. Global assessment of molecular changes in the prostate of the genetically manipulated mice is increasingly underscoring the validity of the models through identification of 'signature' genes which are associated with the organ-confined primary or distant metastases of human prostate cancer. Taken together, various 'natural' models depicting stages of the disease, ranging from the early preneoplastic lesions to metastatic prostate cancer, now provide new tools both for exploring the molecular mechanism underlying prostate cancer and for development or testing of new targeted therapies.
引用
收藏
页码:225 / 254
页数:30
相关论文
共 221 条
[21]  
Bubendorf L, 1999, CANCER RES, V59, P803
[22]   Contribution of the androgen receptor to prostate cancer predisposition and progression [J].
Buchanan, G ;
Irvine, RA ;
Coetzee, GA ;
Tilley, WD .
CANCER AND METASTASIS REVIEWS, 2001, 20 (3-4) :207-223
[23]  
Buchanan G, 2001, CLIN CANCER RES, V7, P1273
[24]   Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer [J].
Burri, N ;
Shaw, P ;
Bouzourene, H ;
Sordat, I ;
Sordat, B ;
Gillet, M ;
Schorderet, D ;
Bosman, FT ;
Chaubert, P .
LABORATORY INVESTIGATION, 2001, 81 (02) :217-229
[26]   SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 [J].
Carrano, AC ;
Eytan, E ;
Hershko, A ;
Pagano, M .
NATURE CELL BIOLOGY, 1999, 1 (04) :193-199
[27]   A decade of molecular biology of retinoic acid receptors [J].
Chambon, P .
FASEB JOURNAL, 1996, 10 (09) :940-954
[28]   The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts [J].
Cheng, MG ;
Olivier, P ;
Diehl, JA ;
Fero, M ;
Roussel, MF ;
Roberts, JM ;
Sherr, CJ .
EMBO JOURNAL, 1999, 18 (06) :1571-1583
[29]  
Cher M L, 2001, Curr Opin Urol, V11, P483, DOI 10.1097/00042307-200109000-00006
[30]   S-Phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase [J].
Chiarle, R ;
Fan, Y ;
Piva, R ;
Boggino, H ;
Skolnik, J ;
Novero, D ;
Palestro, G ;
De Wolf-Peeters, C ;
Chilosi, M ;
Pagano, M ;
Inghirami, G .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (04) :1457-1466